Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of vericiguat in chronic heart failure with reduced ejection fraction
MOH_2021-10-14_010323Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Vericiguat with Placebo (2 arms). Primary endpoint: Composite of cardiovascular death or hospitalization for heart failure. Started Aug 2021; status: active, not recruiting.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on MOH_2021-10-14_010323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-14_010323.